FMFarshad Mirzavi

Farshad Mirzavi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farshad Mirzavi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Together for Health, Stand with Science: A Decade of Global Health Discourse on World Health Day

    by Farshad Mirzavi, Toba Kazemi

    In recent years, World Health Day has evolved from a purely symbolic occasion to a platform for highlighting the most important global health challenges and guiding policy priorities. The theme for 2026, "Together for Health, Stand with Science," emphasizes the importance of collective action and evidence-based decision-making in the face of complex ...

  • A Comprehensive Insight Into the Roles of Exosomal circRNAs in Metabolic Syndrome

    by Azadeh Taherpour, Safieh Ebrahimi, Farshad Mirzavi

    Exosomes are nano‐sized extracellular vesicles that contain specific proteins, nucleic acids, and lipids. These small vesicles are significant in a wide range of physiological and pathological conditions. Circular RNAs (circRNAs) are a subclass of noncoding RNAs that are expressed differently in many tissues and play essential roles in biological function. circRNAs are remarkably stable and prevalent in exosomes. These properties make them ideal candidates for biomedical research. Exosomal circRNAs function as pathogenic regulators, biomarkers, and therapy candidates in various diseases, including metabolic syndrome. Metabolic syndrome is a multifaceted condition distinguished by disruptions in the body's metabolism, encompassing obesity, insulin resistance, diabetes, nonalcoholic fatty liver disease, hyperlipidemia, and atherosclerosis. This syndrome is linked to a high risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. In this review, we provide a comprehensive overview of the roles of exosomal circRNAs in metabolic syndrome, providing recent perspectives on the pathogenesis, diagnosis, and treatment of these complicated disorders.


  • Open Access

    miR-27a/b Level is Associated with ABCA1 Expression and is a Potential PBMC-Based Biomarker for Coronary Artery Disease

    by Farshad Mirzavi, Safieh Ebrahimi, Arezoo Rajabian, Hossein Hosseini, Behnam Alipoor

    Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1 [...] Abstract Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1


  • Hepatoprotective Effects of Rheum turkestanicum Janisch on High-fat Diet-induced Non-alcoholic Fatty Liver Disease in Mice

    by Mohammad Reza Mahdinezhad, Farshad Mirzavi, Sara Hooshmand, Shirin Taraz Jamshidi, Ahmad Ghorbani, Mohammad Soukhtanloo

    Background: Consumption of a high-fat diet (HFD) is one of the main causes of nonalcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. background: Consumption of a high-fat diet (HFD) is one of the main causes of non-alcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on which the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. Objective: This study aimed to evaluate the effect of Rheum turkestanicum Janisch extract (RTE) on HFD-induced NAFLD in BALB/c mice. Materials and Methods: The study was performed with two models of prevention and therapeutic effect of RTE. Serum biochemical markers, histopathology, oxidative stress indicators, and qRTPCR were measured to evaluate the effects of RTE on lipid metabolism disorders in mice feeding with HFD. Results: In the prevention model, compared to the HFD group, RTE treatment decreased the levels of glucose, triglyceride, and cholesterol and improved liver profile markers, oxidative stress, and expression of genes involved in lipid metabolism. Conclusion: The results of this study suggest that RTE has hepatoprotective effects against HFDinduced liver damage by reducing oxidative stress, lipogenesis, and increasing beta-oxidation of free fatty acids.

  • Protective effect of hesperidin-loaded selenium nanoparticles stabilized by chitosan on glutamate-induced toxicity in PC12 cells

    by Zohreh Najafi, Elham Einafshar, Farshad Mirzavi, Hamed Amiri, Mohammad Jalili-Nik, Mohammad Soukhtanloo


  • Combination of Alpha-Lipoic Acid and Auraptene Induces Apoptosis and Prevents Proliferation of the Human U-87 Glioblastoma Cells

    by Azam Izadi, Asie Sadeghi, Mohammad Jalili-Nik, Farshad Mirzavi, Amir R. Afshari, Mohammad Soukhtanloo


  • The Effects of Urolithin B and Auraptene on Quinolinic Acid-induced Toxicity in the SH-SY5Y Neuroblastoma Cell Line

    by Farzaneh Abbasinezhad-Moud, Farshad Mirzavi, Hassan Rakhshandeh, Reza Mohebbati, Fatemeh Forouzanfar, Mohammad Jalili-Nik, Nadia Azadi, Mehdi Sanati, Amir R. Afshari, Mohammad Soukhtanloo

    The pathological accumulation of quinolinic acid (QA) is often associated with neuritis and neuronal cell death in several neurodegenerative diseases, through the overproduction of free radicals. Urolithin B and auraptene have been reported to exert potent antioxidant effects — however, little is known about the protective effects of these compounds against QA-induced neurotoxicity. Therefore, this study aimed to explore the in vitro protective effects of urolithin B and auraptene against QA-induced neurotoxicity in the SH-SY5Y neuroblastoma cell line. The MTT assay was used to evaluate cell viability, and flow cytometry was carried out to evaluate effects on the cell cycle and apoptosis. The intracellular levels of reactive oxygen species (ROS) were also determined. Our findings showed that auraptene at non-toxic concentrations had no protective effect on QA-induced toxicity. However, urolithin B at concentrations of 0.6 μM and 2.5 μM enhanced the viability of cells treated with QA. Moreover, while the percentage of apoptotic cells (i.e. in the sub-G1 phase) was shown to significantly increase after QA treatment, pre-treatment with urolithin B reduced the number of these apoptotic cells. Furthermore, urolithin B, as an antioxidant, also significantly reduced QA-induced ROS production. Our findings suggest that urolithin B may possess potent antioxidant and neuroprotective effects against QA-induced neurotoxicity that merit further investigation.


  • Bee venom induces anti-tumor effects in HT-29 colon cancer cells through regulation of cell proliferation and apoptosis

    by Hossein Saghi, Farshad Mirzavi, Amir R. Afshari, Mohammad Jalili-Nik, Baratali Mashkani, Mohammad Soukhtanloo


  • Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes

    by Mehdi Barati, Farshad Mirzavi, Amin Reza Nikpoor, Mojtaba Sankian, Hasan Namdar Ahmadabad, Anvar Soleimani, Mohammad Mashreghi, Jalil Tavakol Afshar, Mojgan Mohammadi, Mahmoud Reza Jaafari

    Programmed cell death protein-1 (PD-1), as an immune checkpoint molecule, attenuates T-cell activity and induces T-cell exhaustion. Although siRNA has a great potential in cancer immunotherapy, its delivery to target cells is the main limitation of using siRNA. This study aimed to prepare a liposomal formulation as a siRNA carrier to silence PD-1 expression in T cells and investigate it’s in vivo antitumor efficacy. The liposomal siRNA was prepared and characterized by size, zeta potential, and biodistribution. Following that, the uptake assay and mRNA silencing were evaluated in vitro at mRNA and protein levels. siRNA-PD-1 (siPD-1)-loaded liposome nanoparticles were injected into B16F0 tumor-bearing mice to evaluate tumor growth, tumor-infiltrating lymphocytes, and survival rate. Liposomal siPD-1 efficiently silenced PD-1 mRNA expression in T cells (P < 0.0001), and siPD-1-loaded liposomal nanoparticles enhanced the infiltration of T-helper 1 (Th 1) and cytotoxic T lymphocytes into the tumor tissue (P < 0.0001). Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.